Last reviewed 2026-04-19 · How we verify

GUANOXAN

Phase 2 active Small molecule

GUANOXAN is a guanoxan drug. It is currently in Phase 2 development.

GUANOXAN is thought to work by relaxing blood vessels, which can help lower blood pressure.

GUANOXAN is a small molecule drug in the guanoxan class, but specific details about its development, approval status, and commercial availability are not readily available. As a guanoxan, it is likely a vasodilator, but its exact mechanism and target are unknown. Further research is needed to understand its potential therapeutic applications and safety profile. Its commercial status, including patent status and generic availability, is also unclear. Overall, GUANOXAN appears to be a relatively obscure compound with limited information available.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GUANOXAN
Drug class	guanoxan
Modality	Small molecule
Therapeutic area	Hematology
Phase	Phase 2

Mechanism of action

Imagine your blood vessels as a narrow road. When they're constricted, it's like a traffic jam, and blood pressure goes up. GUANOXAN helps to widen these roads, allowing blood to flow more easily and reducing pressure on the heart.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GUANOXAN CI brief — competitive landscape report
GUANOXAN updates RSS · CI watch RSS

Frequently asked questions about GUANOXAN

What is GUANOXAN?

GUANOXAN is a guanoxan drug.

How does GUANOXAN work?

GUANOXAN is thought to work by relaxing blood vessels, which can help lower blood pressure.

What drug class is GUANOXAN in?

GUANOXAN belongs to the guanoxan class. See all guanoxan drugs at /class/guanoxan.

What development phase is GUANOXAN in?

GUANOXAN is in Phase 2.

Drug class: All guanoxan drugs
Therapeutic area: All drugs in Hematology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing